| Amy M Neville, MD | |
|
2799 W Grand Blvd, Detroit, MI 48202-2608 | |
| (800) 653-6568 | |
| Not Available |
| Full Name | Amy M Neville |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 2799 W Grand Blvd, Detroit, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346446598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301080414 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry Ford Hospital | Detroit, MI | Hospital |
| Henry Ford West Bloomfield Hospital | West bloomfield, MI | Hospital |
| Henry Ford Macomb Hospital | Clinton township, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Henry Ford Medical Group | 0547178311 | 2095 |
| Troy Internal Medicine, Pc | 0840282067 | 27 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
| Entity Name | Henry Ford Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144801 PECOS PAC ID: 0547178311 Enrollment ID: O20031105000139 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
| Entity Name | Henry Ford Macomb Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134265986 PECOS PAC ID: 7911808381 Enrollment ID: O20040119000142 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
| Entity Name | Troy Internal Medicine, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356450589 PECOS PAC ID: 0840282067 Enrollment ID: O20040330001398 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
| Entity Name | Henry Ford Urgent Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184389876 PECOS PAC ID: 6901296110 Enrollment ID: O20211202000908 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy M Neville, MD 1 Ford Pl Ste 2e, Detroit, MI 48202-3450 Ph: (313) 874-4806 | Amy M Neville, MD 2799 W Grand Blvd, Detroit, MI 48202-2608 Ph: (800) 653-6568 |
News Archive
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
How well women with cervical cancer respond to treatment and survive correlates with the level of 10 proteins in their blood that also are associated with a "zombie" cell state called senescence, Medical College of Georgia scientists report.
When it comes to what's for dinner - or breakfast and lunch for that matter- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 8 days ago
Dr. Brent David Griffith, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Kanika Khanna, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Dr. Michael Matthew Dominello, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 4100 John R, Detroit, MI 48201 Phone: 800-527-6266 Fax: 313-576-9640 | |
Rajinder P. Sharma, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 Phone: 313-916-2436 | |
Milan V. Pantelic, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 Phone: 313-916-2436 | |
Kristan Gail Jenkins-mosure, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 800-653-6568 | |
Kristin Booth, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 517-402-1383 |